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ulcerative colitis 1081

underexpression 732

uPAR 564

urban and rural area 1261

urokinase plasminogen activator (uPA) 1308

uterine cervical cancer 466

utility 1893

UVC resistance 1669

uvea 1495

vaccine 817

vascularity 1181

VDR 765

VEGF 219, 498, 1174, 1181, 1391

VEGF-C 466

VEGFR2 1391

venous thromboembolism 92

vinorelbine 489

vitamin D 1425

waiting times 1477

website 355

weekly schedule 1996

worry 1787

WWOX gene expression 753

xenograft 1205

X-linked inhibitor of apoptosis 1349

XR11576 1459

XRCC1 1604

ZD1839 208

ZD6474 1174

zinc-finger protein 1566
